Insulin Maker Learns Brutal Lesson: Sometimes Innovation Doesn’t Pay

For almost a century, Novo Nordisk rolled out new versions of its core product at higher prices. Then suddenly, customers including governments and insurers decided the older, less expensive versions were good enough.

Popular Posts


(Visited 2 times, 1 visits today)

Vote on this story -->>>

this is a single

THE MIAMI METROPOLIS -your source for news, music, sports, movies, restaurants, reviews, weather, travel, arts, tech and events in Miami